Projected 12-Month Target for SPLG by Analysts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 18 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The SPDR Portfolio S&P 500 ETF (SPLG) has an implied analyst target price of $83.28, indicating a potential upside of 9.99% from its current trading price of $75.71.
Notable Holdings: Key underlying holdings with significant upside include Prologis Inc (PLD), Chubb Ltd (CB), and Trane Technologies plc (TT), with expected increases of 11.92%, 10.75%, and 10.65% respectively.
Analyst Target Justification: Questions arise regarding whether analysts' target prices are justified or overly optimistic, considering recent company and industry developments.
Investor Research Needed: Further research is recommended for investors to assess the validity of these targets and avoid potential downgrades based on outdated expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CB
Wall Street analysts forecast CB stock price to rise
17 Analyst Rating
7 Buy
8 Hold
2 Sell
Moderate Buy
Current: 325.120
Low
283.00
Averages
336.88
High
385.00
Current: 325.120
Low
283.00
Averages
336.88
High
385.00
About CB
Chubb Limited is a Switzerland-based holding company. The Company, through its subsidiaries, provides a range of insurance and reinsurance products and services to clients around the world. Its segments include North America Commercial property and casualty (P&C) Insurance, North America Personal P&C Insurance, North America Agricultural Insurance, Overseas General Insurance, Global Reinsurance and Life Insurance. It offers commercial insurance products and service offerings, such as risk management programs, loss control, and engineering and complex claims management. It provides specialized insurance products to areas, such as aviation and energy. It also offers personal lines insurance coverage, including homeowners, automobile, valuables, umbrella liability and recreational marine products. In addition, it supplies personal accident, supplemental health and life insurance to individuals in select countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chubb Expected to Announce Dividend Increase
- Dividend Growth Expectation: Chubb is expected to announce a dividend increase this May, continuing its 29-year streak of regular dividend growth, with analysts forecasting an annual dividend of about $4.00 per share, translating to a quarterly dividend of approximately $1 per share, reflecting a 3.09% increase from last year's $0.970 payout.
- Historical Growth Trend: In April last year, Chubb raised its dividend from $0.91 to $0.97, marking a 6.59% increase, while the company has achieved a 2.25% annual dividend growth rate over the past five years, demonstrating stability in returning value to shareholders.
- Dividend Quality Ratings: Chubb exhibits strong performance in dividend quality metrics, with safety rated at A-, growth rated at A, yield rated at D, and consistency rated at A+, indicating the company's reliability and stability in dividend payments.
- Payout Ratio: Currently, Chubb maintains a payout ratio of 13.87%, suggesting that a relatively small portion of its earnings is allocated to dividends, reflecting a healthy financial position that supports continued dividend growth in the future.
See More
Analysis of Investment Opportunities in Dividend Stocks
- Dividend Growth Potential: Trivariate Research highlights that the median dividend growth rate among 479 large-cap stocks is 5% annually, with these stocks outperforming the top 700 equities over both 25-year and 5-year periods, underscoring the significance of dividends as a durable return factor.
- Low Payout Ratio Advantage: The study found that stocks in the lowest payout ratio quintiles performed best over the past five years, particularly those with cash to market cap above 25%, as they significantly outperform others when increasing dividends, reflecting strong financial health.
- Synchrony Financial's Dividend Increase: Synchrony Financial announced a 13% dividend increase to $0.34 per share and a share repurchase program of up to $6.5 billion, demonstrating confidence in long-term shareholder value, despite its stock being down nearly 11% year to date.
- Travelers Insurance's Sustained Growth: Travelers Insurance declared a 14% increase in its quarterly dividend to $1.25 per share, marking its 22nd consecutive year of increases with an 8% compound annual growth rate, showcasing its ability to deliver industry-leading returns with low volatility.
See More
Verified Clinical Trials Forms Strategic Alliance with Chubb
- Strategic Partnership Highlights: Verified Clinical Trials (VCT) has formed a strategic alliance with leading insurer Chubb, aiming to enhance participant safety and data quality, thereby improving the overall effectiveness of clinical trials and providing a more reliable research environment for pharmaceutical and biotech companies.
- Innovative Risk Management: This collaboration combines VCT's participant registration technology with Chubb's insurance expertise, effectively identifying and preventing issues like duplicate participation, reducing the risk of clinical trial failures, and ensuring data integrity and compliance in research.
- Industry Impact: As a market leader in clinical trial insurance, Chubb will provide clients with additional protection against adverse events and data quality issues, further enhancing client confidence in clinical research and facilitating the development of new drugs and therapies.
- Future Outlook: The partnership between VCT and Chubb represents a significant advancement in clinical research risk management, promoting the industry towards greater transparency and safety, ultimately enabling patients to receive new drugs and treatments more safely.
See More
Verified Clinical Trials and Chubb Form Strategic Alliance
- Strategic Partnership Highlights: Verified Clinical Trials (VCT) has formed a strategic alliance with global insurance leader Chubb, aimed at enhancing clinical trial success rates by optimizing data quality and improving research participant safety, thereby providing a more reliable research environment for pharmaceutical and biotech companies.
- Innovative Risk Management: This collaboration combines VCT's participant registration technology with Chubb's insurance solutions to effectively prevent duplicate registrations and protocol violations, reducing safety risks in clinical trials and enhancing data integrity and the credibility of research outcomes.
- Industry Impact: As a leader in clinical trial insurance, Chubb leverages its extensive industry experience and international capabilities to offer tailored insurance solutions to clients ranging from startups to large pharmaceutical companies, helping them better manage potential adverse events and data quality issues.
- Future Outlook: The partnership between VCT and Chubb not only enhances the safety and transparency of clinical research but also marks a significant step towards proactive risk management in the industry, which is expected to drive the development of safer and more effective drugs and therapies, ultimately benefiting patients and the public.
See More
VCT and Chubb Form Strategic Alliance
- Strategic Partnership: Verified Clinical Trials (VCT) has formed a strategic alliance with global insurance leader Chubb, aimed at enhancing the safety of clinical research subjects and data integrity, thereby increasing the success rate of clinical trials.
- Technological Edge: VCT's unique technology can detect double recruitment and other protocol violations in real-time, which not only prevents potential safety hazards but also improves data quality and reduces the risk of study failures.
- Market Impact: As a leading global clinical trial insurer, Chubb will provide additional protection to pharmaceutical and biotechnology companies, leveraging its extensive experience and international capabilities to enhance their competitiveness in the market.
- Industry Outlook: This collaboration marks a significant advancement in clinical trial risk management, expected to drive the industry towards a safer, more transparent, and reliable direction, ultimately benefiting patients with safer and more effective treatment options.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Alliance Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing research subject safety and data quality through VCT's proprietary subject registry technology, thereby reducing the risk of clinical trial failures and strengthening study integrity.
- Integrated Insurance Solutions: Chubb, as a leading global underwriter of clinical trials, combines its insurance capabilities with VCT's registry technology to provide pharmaceutical and biotechnology companies with additional protection against duplicate enrollment and other protocol violations during trials.
- Industry Impact Enhancement: This collaboration not only offers stronger protocol compliance and data integrity assurances for research sites and Contract Research Organizations (CROs) but also improves overall clinical trial execution by mitigating preventable risks.
- Proactive Risk Management: The partnership between VCT and Chubb signifies a shift in clinical research risk management from reactive measures to proactive safeguards, aiming to deliver safer and more effective drugs and therapies, thus advancing the entire clinical research ecosystem.
See More
Chubb Expected to Announce Dividend Increase
- Dividend Growth Expectation: Chubb is expected to announce a dividend increase this May, continuing its 29-year streak of regular dividend growth, with analysts forecasting an annual dividend of about $4.00 per share, translating to a quarterly dividend of approximately $1 per share, reflecting a 3.09% increase from last year's $0.970 payout.
- Historical Growth Trend: In April last year, Chubb raised its dividend from $0.91 to $0.97, marking a 6.59% increase, while the company has achieved a 2.25% annual dividend growth rate over the past five years, demonstrating stability in returning value to shareholders.
- Dividend Quality Ratings: Chubb exhibits strong performance in dividend quality metrics, with safety rated at A-, growth rated at A, yield rated at D, and consistency rated at A+, indicating the company's reliability and stability in dividend payments.
- Payout Ratio: Currently, Chubb maintains a payout ratio of 13.87%, suggesting that a relatively small portion of its earnings is allocated to dividends, reflecting a healthy financial position that supports continued dividend growth in the future.
See More
Analysis of Investment Opportunities in Dividend Stocks
- Dividend Growth Potential: Trivariate Research highlights that the median dividend growth rate among 479 large-cap stocks is 5% annually, with these stocks outperforming the top 700 equities over both 25-year and 5-year periods, underscoring the significance of dividends as a durable return factor.
- Low Payout Ratio Advantage: The study found that stocks in the lowest payout ratio quintiles performed best over the past five years, particularly those with cash to market cap above 25%, as they significantly outperform others when increasing dividends, reflecting strong financial health.
- Synchrony Financial's Dividend Increase: Synchrony Financial announced a 13% dividend increase to $0.34 per share and a share repurchase program of up to $6.5 billion, demonstrating confidence in long-term shareholder value, despite its stock being down nearly 11% year to date.
- Travelers Insurance's Sustained Growth: Travelers Insurance declared a 14% increase in its quarterly dividend to $1.25 per share, marking its 22nd consecutive year of increases with an 8% compound annual growth rate, showcasing its ability to deliver industry-leading returns with low volatility.
See More
Verified Clinical Trials Forms Strategic Alliance with Chubb
- Strategic Partnership Highlights: Verified Clinical Trials (VCT) has formed a strategic alliance with leading insurer Chubb, aiming to enhance participant safety and data quality, thereby improving the overall effectiveness of clinical trials and providing a more reliable research environment for pharmaceutical and biotech companies.
- Innovative Risk Management: This collaboration combines VCT's participant registration technology with Chubb's insurance expertise, effectively identifying and preventing issues like duplicate participation, reducing the risk of clinical trial failures, and ensuring data integrity and compliance in research.
- Industry Impact: As a market leader in clinical trial insurance, Chubb will provide clients with additional protection against adverse events and data quality issues, further enhancing client confidence in clinical research and facilitating the development of new drugs and therapies.
- Future Outlook: The partnership between VCT and Chubb represents a significant advancement in clinical research risk management, promoting the industry towards greater transparency and safety, ultimately enabling patients to receive new drugs and treatments more safely.
See More
Verified Clinical Trials and Chubb Form Strategic Alliance
- Strategic Partnership Highlights: Verified Clinical Trials (VCT) has formed a strategic alliance with global insurance leader Chubb, aimed at enhancing clinical trial success rates by optimizing data quality and improving research participant safety, thereby providing a more reliable research environment for pharmaceutical and biotech companies.
- Innovative Risk Management: This collaboration combines VCT's participant registration technology with Chubb's insurance solutions to effectively prevent duplicate registrations and protocol violations, reducing safety risks in clinical trials and enhancing data integrity and the credibility of research outcomes.
- Industry Impact: As a leader in clinical trial insurance, Chubb leverages its extensive industry experience and international capabilities to offer tailored insurance solutions to clients ranging from startups to large pharmaceutical companies, helping them better manage potential adverse events and data quality issues.
- Future Outlook: The partnership between VCT and Chubb not only enhances the safety and transparency of clinical research but also marks a significant step towards proactive risk management in the industry, which is expected to drive the development of safer and more effective drugs and therapies, ultimately benefiting patients and the public.
See More
VCT and Chubb Form Strategic Alliance
- Strategic Partnership: Verified Clinical Trials (VCT) has formed a strategic alliance with global insurance leader Chubb, aimed at enhancing the safety of clinical research subjects and data integrity, thereby increasing the success rate of clinical trials.
- Technological Edge: VCT's unique technology can detect double recruitment and other protocol violations in real-time, which not only prevents potential safety hazards but also improves data quality and reduces the risk of study failures.
- Market Impact: As a leading global clinical trial insurer, Chubb will provide additional protection to pharmaceutical and biotechnology companies, leveraging its extensive experience and international capabilities to enhance their competitiveness in the market.
- Industry Outlook: This collaboration marks a significant advancement in clinical trial risk management, expected to drive the industry towards a safer, more transparent, and reliable direction, ultimately benefiting patients with safer and more effective treatment options.
See More
VCT and Chubb Form Strategic Alliance to Enhance Clinical Trial Safety
- Strategic Alliance Highlights: Verified Clinical Trials (VCT) and Chubb have formed a strategic alliance aimed at enhancing research subject safety and data quality through VCT's proprietary subject registry technology, thereby reducing the risk of clinical trial failures and strengthening study integrity.
- Integrated Insurance Solutions: Chubb, as a leading global underwriter of clinical trials, combines its insurance capabilities with VCT's registry technology to provide pharmaceutical and biotechnology companies with additional protection against duplicate enrollment and other protocol violations during trials.
- Industry Impact Enhancement: This collaboration not only offers stronger protocol compliance and data integrity assurances for research sites and Contract Research Organizations (CROs) but also improves overall clinical trial execution by mitigating preventable risks.
- Proactive Risk Management: The partnership between VCT and Chubb signifies a shift in clinical research risk management from reactive measures to proactive safeguards, aiming to deliver safer and more effective drugs and therapies, thus advancing the entire clinical research ecosystem.
See More
